Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
68.30 USD   +4.42%
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year Outcomes from the Randomized Phase 3 OAKS and DERBY Trials
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Event chart APELLIS PHARMACEUTICALS, INC.
Upcoming events on APELLIS PHARMACEUTICALS, INC.
10/02/22 | 09:12am American Academy of Ophthalmology Meeting - PA024
10/02/22 | 05:45pm American Academy of Ophthalmology Meeting - PA069
11/07/22 Q3 2022 Earnings Release (Projected)
02/27/23 FY 2022 Earnings Release (Projected)
05/03/23 Q1 2023 Earnings Release (Projected)
08/07/23 Interim 2023 Earnings Release (Projected)
Past events on APELLIS PHARMACEUTICALS, INC.
10/01/22 | 04:13pm American Academy of Ophthalmology Meeting - RET19
09/30/22 | 05:30pm American Academy of Ophthalmology Meeting - RET10
09/30/22 American Academy of Ophthalmology Meeting - PO427
09/16/22 | 04:55am Bank of America Merrill Lynch Global Healthcare Conference - Fireside Chat
09/14/22 | 03:10pm Baird Global Healthcare Conference
09/08/22 | 01:55pm Wells Fargo Healthcare Conference
09/07/22 | 01:00pm Citi BioPharma Conference
08/24/22 | 08:30am DERBY and OAKS Phase 3 Study Results Call
08/08/22 | 04:30pm Interim 2022 Earnings Call
08/08/22 | 04:05pm Interim 2022 Earnings Release
Past dividends on APELLIS PHARMACEUTICALS, INC.

- No events available -

Annual results
Fiscal Period : December201720182019202020212022
Sales
M $
Released
Forecast
Spread


 


 


 
251
98,4
155%
66,6
15,0
344%
 
79,1
 
Operating income
(EBITDA)
M $
Released
Forecast
Spread
-50,8
-45,7
-11%
-128
-127
-0,73%
-288
-247
-17%
-213
-377
43%
-535
-560
4,5%
 
-567
 
Operating profit
(EBIT)
M $
Released
Forecast
Spread
-50,8
-30,0
-69%
-128
-130
1,5%
-288
-255
-13%
-214
-373
43%
-536
-580
7,6%
 
-587
 
Pre-Tax Profit
(EBT)
M $
Released
Forecast
Spread
-51,0
-45,0
-13%
-128
-131
2,5%
-305
-263
-16%
-343
-449
24%
-746
-736
-1,3%
 
-630
 
Net income
M $
Released
Forecast
Spread
-51,0
-45,5
-12%
-128
-131
2,5%
-305
-264
-15%
-345
-458
25%
-746
-724
-3,1%
 
-627
 
EPS
$
Released
Forecast
Spread
-3,68
-0,92
-298%
-2,34
-2,40
2,6%
-4,90
-4,23
-16%
-4,59
-5,95
23%
-8,84
-8,66
-2,1%
 
-5,96
 
Announcement Date03/19/201802/26/201902/27/202002/25/202102/28/2022-
Quarterly results
Fiscal Period : December2021 Q22021 Q32021 Q42022 Q12022 Q22022 Q3
Sales
M $
Released
Forecast
Spread
0,62
0,46
34%
5,65
7,23
-22%
60,3
8,78
586%
14,4
12,6
14%
16,3
16,9
-3,7%
 
21,7
 
Operating income
(EBITDA)
M $
Released
Forecast
Spread
-194
-132
-47%
-128
-135
5,7%
-89,0
-121
26%
-129
-105
-22%
-148
-116
-28%
 
-120
 
Operating profit
(EBIT)
M $
Released
Forecast
Spread
-194
-134
-45%
-128
-143
11%
-89,4
-137
35%
-129
-129
-0,03%
-149
-138
-7,8%
 
-150
 
Pre-Tax Profit
(EBT)
M $
Released
Forecast
Spread
-219
-132
-67%
-196
-144
-36%
-148
-136
-8,9%
-138
-128
-7,9%
-155
-141
-9,9%
 
-156
 
Net income
M $
Released
Forecast
Spread
-219
-136
-61%
-196
-145
-35%
-148
-133
-12%
-139
-130
-6,9%
-156
-144
-8,3%
 
-157
 
EPS
$
Released
Forecast
Spread
-2,72
-1,69
-61%
-2,28
-1,71
-33%
-1,61
-1,49
-8,1%
-1,42
-1,30
-8,9%
-1,46
-1,37
-6,4%
 
-1,45
 
Announcement Date08/09/202111/08/202102/28/202205/04/202208/08/2022-
Previous year Next Year
Upcoming sector events for APELLIS PHARMACEUTICALS, INC.
More events
Past sector events for APELLIS PHARMACEUTICALS, INC.
More events
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise